The associations of physical activity and television TV viewing with mortality risk among individuals with hematologic malignancies remain unclear. We examined the relations of physical activity and TV viewing time before and after diagnosis with mortality among U. For the pre- and post-diagnosis analyses, we confirmed and deaths respectively. Additional control for BMI had little impact on the results, expect for myeloma survivors, for whom the association was no longer significant.
The associations for TV viewing did not show a clear pattern. Our study suggests that pre- and post-diagnosis physical activity is associated with lower risk of all-cause mortality among hematologic cancer survivors.
Further research is required to confirm this observation. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: All relevant data are within the paper and its Supporting Information files. Competing interests: The authors have declared that no competing interests exist. Hematologic cancers represent a group of malignant neoplasms of the hematopoietic and lymphoid tissues comprising Hodgkin lymphoma HL , non-Hodgkin lymphoma NHL , multiple myeloma, and leukemia.
The survival rates for hematologic cancer have increased notably during the past few decades [ 1 ], seemingly as a result of improved diagnosis and health care services, and population aging. Cancer patients frequently experience fatigue, depression, and decreased physical function and quality of life, which are partly the consequences of cancer treatment [ 2 β 7 ].
Moreover, they are at increased risk of cancer recurrence, second malignancies, other chronic diseases, and premature death [ 8 β 10 ]. Exercise plays numerous roles to improve health among individuals presenting with cancer [ 11 , 12 ], yet it remains unclear whether physical activity improves survival among hematologic cancer patients.
